Paxmedica Common Stock Stock Alpha and Beta Analysis
| PXMD Stock | USD 0.0001 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as PaxMedica Common Stock. It also helps investors analyze the systematic and unsystematic risks associated with investing in PaxMedica Common over a specified time horizon. Remember, high PaxMedica Common's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to PaxMedica Common's market risk premium analysis include:
Beta (47.76) | Alpha 75.33 | Risk 217.42 | Sharpe Ratio 0.19 | Expected Return 41.38 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
PaxMedica |
PaxMedica Common Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. PaxMedica Common market risk premium is the additional return an investor will receive from holding PaxMedica Common long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in PaxMedica Common. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate PaxMedica Common's performance over market.| α | 75.33 | β | -47.76 |
PaxMedica Common expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of PaxMedica Common's Buy-and-hold return. Our buy-and-hold chart shows how PaxMedica Common performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.PaxMedica Common Market Price Analysis
Market price analysis indicators help investors to evaluate how PaxMedica Common pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading PaxMedica Common shares will generate the highest return on investment. By understating and applying PaxMedica Common pink sheet market price indicators, traders can identify PaxMedica Common position entry and exit signals to maximize returns.
PaxMedica Common Return and Market Media
The median price of PaxMedica Common for the period between Mon, Oct 13, 2025 and Sun, Jan 11, 2026 is 1.0E-4 with a coefficient of variation of 240.01. The daily time series for the period is distributed with a sample standard deviation of 0.0, arithmetic mean of 0.0, and mean deviation of 0.0. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
About PaxMedica Common Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including PaxMedica or other pink sheets. Alpha measures the amount that position in PaxMedica Common Stock has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
PaxMedica Common Upcoming Company Events
As portrayed in its financial statements, the presentation of PaxMedica Common's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PaxMedica Common's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of PaxMedica Common's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of PaxMedica Common. Please utilize our Beneish M Score to check the likelihood of PaxMedica Common's management manipulating its earnings.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with PaxMedica Common
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Other Information on Investing in PaxMedica Pink Sheet
PaxMedica Common financial ratios help investors to determine whether PaxMedica Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PaxMedica with respect to the benefits of owning PaxMedica Common security.